Keros gives Han­soh sub­sidiary li­cense for lead drug in $190M+ deal; Vac­citech snaps up new tools in small buy­out 

Mass­a­chu­setts biotech Keros Ther­a­peu­tics now has a deal with Han­soh Healthtech, a Han­soh Phar­ma­ceu­ti­cal Group sub­sidiary, in the form of an ex­clu­sive li­cense.

The deal was an­nounced ear­li­er this week, with Han­soh get­ting the li­cense from Keros to de­vel­op, man­u­fac­ture and com­mer­cial­ize KER-050 with­in Chi­na, Hong Kong and Macau.

KER-050, an en­gi­neered lig­and trap and Keros’ lead drug can­di­date, is in Phase II tri­als for myelodys­plas­tic syn­drome and a bone mar­row can­cer known as myelofi­bro­sis. The drug is de­signed to in­crease the pro­duc­tion of platelets and red blood cells and treat low blood cell counts such as ane­mia, ac­cord­ing to Keros.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.